Pharma BD Deal Intelligence
INOmax kept generating hundreds of millions a year, but the ~$795M of Ikaria goodwill was wiped out in 2018 and Mallinckrodt itself went bankrupt twice — a product that survived inside a deal that didn't pay off
Full analysis, sources & comparables →Mallinckrodt's $2.3B Ikaria buy is a drug-device combination play centered on INOMAX, with the bundled service model providing a meaningful moat around an…
The Ikaria deal adds a high-margin neonatal critical-care franchise that extends Mallinckrodt's hospital footprint and is immediately accretive by at least…
A federal judge's invalidation of key INOMAX delivery-system patents reopened the iNO market to Praxair and other entrants, undercutting the moat thesis behind…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Mallinckrodt acquired Ikaria from Madison Dearborn-led investor group for ~$2.3B, expanding into neonatal critical care and adding INOMAX (inhaled nitric oxide) drug-device platform. Closed April 16, 2015.
INOmax kept generating hundreds of millions a year, but the ~$795M of Ikaria goodwill was wiped out in 2018 and Mallinckrodt itself went bankrupt twice — a product that survived inside a deal that didn't pay off
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mallinckrodt plc / Ikaria, Inc. (this deal) | 2015 | $2.3B | 37 |
| Mallinckrodt plc / Cadence Pharmaceuticals, Inc. | 2014 | $1.4B | 50 |
| Mallinckrodt plc / Therakos, Inc. | 2015 | $1.3B | 48 |
| Mallinckrodt plc / Sucampo Pharmaceuticals, Inc. | 2017 | $1.2B | 19 |
| Mallinckrodt plc / Questcor Pharmaceuticals, Inc. | 2014 | $5.6B | 18 |
| Mallinckrodt plc / InfaCare Pharmaceutical Corporation | 2017 | $425M | 12 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
← Browse all deals · How we score deals
More: 2015 deals · Mallinckrodt plc deals · Cardiovascular deals